Leaflet AROMASIN 25mg sugar-coated tablets

Product code:
W65092001
Quantity:
30
Indicated for:
breast cancer
Route of administration:
oral
Substance:
exemestane (aromatase inhibitor)
ATC
L02BG06 — Antineoplastic and immunomodulating agents | Hormone antagonists and related agents | Aromatase inhibitors
Exemestane is a medication used in the treatment of hormone-dependent breast cancer in postmenopausal women. It belongs to the class of aromatase inhibitors and works by reducing estrogen levels in the body, which slows or stops the growth of tumors that require estrogen to grow.

It is indicated for the treatment of early-stage breast cancer after tamoxifen therapy or for advanced or metastatic breast cancer. Exemestane is taken orally in tablet form, usually once daily after a meal.

Side effects may include hot flashes, fatigue, joint or muscle pain, insomnia, nausea, osteoporosis or decreased bone density, and excessive sweating. Rarely, allergic reactions or liver disorders may occur.

Exemestane is contraindicated in premenopausal women, during pregnancy, or while breastfeeding. It is important to take the medication as prescribed by a doctor, and patients should be monitored regularly to assess effectiveness and potential side effects.

General data about AROMASIN 25mg

Substance:
exemestane
Date of latest medicines list:
01-06-2026
Product code:
W65092001
Concentration:
25mg
Pharmaceutical form:
sugar-coated tablets
Quantity:
30
Product type:
Original
Price:
116.70 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
PFIZER ITALIA S.R.L. - ITALIA
Holder:
PFIZER EUROPE MA EEIG - BELGIA
Number:
6157/2014/01
Shelf life:
3 years

Pharmaceutical forms available for exemestane

Compensation lists for AROMASIN 25mg Pfizer

NHP 3 (C2) - NHP oncology

Price
116.70 RON
Copayment
109.70 RON
Patient
7.00 RON